AR071810A1 - Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. - Google Patents

Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.

Info

Publication number
AR071810A1
AR071810A1 ARP090101762A ARP090101762A AR071810A1 AR 071810 A1 AR071810 A1 AR 071810A1 AR P090101762 A ARP090101762 A AR P090101762A AR P090101762 A ARP090101762 A AR P090101762A AR 071810 A1 AR071810 A1 AR 071810A1
Authority
AR
Argentina
Prior art keywords
acute
relaxin
heart failure
decompensated
human subject
Prior art date
Application number
ARP090101762A
Other languages
English (en)
Spanish (es)
Inventor
Martha Jo Whitehouse
Sam L Teichman
Elaine Unemori
Gad Cotter
Dennis Stewart
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of AR071810A1 publication Critical patent/AR071810A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP090101762A 2008-05-16 2009-05-15 Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. AR071810A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
AR071810A1 true AR071810A1 (es) 2010-07-14

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101762A AR071810A1 (es) 2008-05-16 2009-05-15 Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.

Country Status (30)

Country Link
US (7) US8053411B2 (enExample)
EP (2) EP2829280A1 (enExample)
JP (4) JP5651586B2 (enExample)
CN (3) CN102036679A (enExample)
AR (1) AR071810A1 (enExample)
AU (1) AU2009246114B2 (enExample)
BR (1) BRPI0913011A2 (enExample)
CA (1) CA2724540C (enExample)
CR (1) CR11749A (enExample)
CY (1) CY1116925T1 (enExample)
DK (1) DK2288373T3 (enExample)
EA (2) EA022948B1 (enExample)
ES (1) ES2546287T3 (enExample)
GB (2) GB2462221B (enExample)
HK (1) HK1202054A1 (enExample)
HR (1) HRP20150845T1 (enExample)
HU (1) HUE025483T2 (enExample)
IL (3) IL208992A (enExample)
MA (1) MA32389B1 (enExample)
MX (1) MX2010012450A (enExample)
MY (2) MY159803A (enExample)
NZ (3) NZ589009A (enExample)
PL (1) PL2288373T3 (enExample)
PT (1) PT2288373E (enExample)
SG (2) SG10201609580YA (enExample)
SI (1) SI2288373T1 (enExample)
TW (1) TWI386202B (enExample)
UA (1) UA99953C2 (enExample)
WO (1) WO2009140659A2 (enExample)
ZA (1) ZA201007449B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246112B2 (en) * 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
MX2012010382A (es) * 2010-03-10 2013-01-29 Univ Melbourne Modulacion de acuaporinas con relaxina.
US8501418B2 (en) * 2010-08-06 2013-08-06 Pronata N.V. Method of treating renal dysfunction based on perlecan as a biomarker
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2742296T3 (es) * 2010-08-17 2020-02-13 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
KR102107482B1 (ko) * 2012-02-14 2020-05-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
KR102299073B1 (ko) 2012-10-26 2021-09-09 치에시 파마슈티시 에스.피.아. 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법
US9884039B2 (en) 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201605273XA (en) * 2014-02-03 2016-08-30 Novartis Ag Filters for infusion sets
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
DK3387019T3 (da) 2015-12-09 2022-01-10 Scripps Research Inst Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
WO2020141224A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
AU2020214314B2 (en) 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
EP4580653A1 (en) 2022-08-31 2025-07-09 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
EP0675732B1 (en) * 1993-07-27 2006-06-28 Mario Bigazzi Use of relaxin in the manufacture of therapeutic agents
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
EP0845992B1 (en) 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
CA2397200C (en) * 2000-02-09 2010-11-23 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US20070202080A1 (en) 2004-03-30 2007-08-30 Industry-University Cooperation Foundation Yonsei Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
WO2007008907A2 (en) 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
JP5355561B2 (ja) 2007-07-12 2013-11-27 コンピュゲン エルティーディー． 生物活性ペプチドおよびその使用方法
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
AU2009246112B2 (en) 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure

Also Published As

Publication number Publication date
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US20120040902A1 (en) 2012-02-16
MY158327A (en) 2016-09-30
CN102036679A (zh) 2011-04-27
US20130210730A1 (en) 2013-08-15
JP5651586B2 (ja) 2015-01-14
JP2011520918A (ja) 2011-07-21
HUE025483T2 (en) 2016-02-29
CR11749A (es) 2011-02-11
NZ701038A (en) 2016-01-29
TWI386202B (zh) 2013-02-21
US20170151311A1 (en) 2017-06-01
AU2009246114B2 (en) 2013-01-31
CN106177914A (zh) 2016-12-07
JP2016053040A (ja) 2016-04-14
HK1202054A1 (en) 2015-09-18
UA99953C2 (uk) 2012-10-25
JP5875646B2 (ja) 2016-03-02
US20100048475A1 (en) 2010-02-25
EA201001771A1 (ru) 2011-06-30
NZ598709A (en) 2013-09-27
US20150320834A1 (en) 2015-11-12
GB2459983B (en) 2010-04-28
CA2724540C (en) 2014-07-08
MX2010012450A (es) 2011-03-21
JP2015013870A (ja) 2015-01-22
JP5638044B2 (ja) 2014-12-10
WO2009140659A2 (en) 2009-11-19
WO2009140659A3 (en) 2010-07-22
TW200948353A (en) 2009-12-01
GB0918132D0 (en) 2009-12-02
GB2459983A (en) 2009-11-18
MY159803A (en) 2017-02-15
SG10201609580YA (en) 2016-12-29
DK2288373T3 (en) 2015-09-28
HK1187550A1 (zh) 2014-04-11
BRPI0913011A2 (pt) 2019-09-03
AU2009246114A1 (en) 2009-11-19
EP2288373A2 (en) 2011-03-02
JP2013040174A (ja) 2013-02-28
PL2288373T3 (pl) 2015-11-30
EA022948B1 (ru) 2016-03-31
US8053411B2 (en) 2011-11-08
CN103212063A (zh) 2013-07-24
ZA201007449B (en) 2011-06-29
HK1151229A1 (en) 2012-01-27
US8415301B2 (en) 2013-04-09
US20130116181A1 (en) 2013-05-09
US9579363B2 (en) 2017-02-28
US20120040903A1 (en) 2012-02-16
HK1139051A1 (en) 2010-09-10
CN103212063B (zh) 2015-07-22
US8372809B2 (en) 2013-02-12
EA201500552A1 (ru) 2016-07-29
CY1116925T1 (el) 2017-04-05
IL208992A (en) 2013-09-30
SI2288373T1 (sl) 2015-12-31
SG191587A1 (en) 2013-07-31
US9205132B2 (en) 2015-12-08
EP2829280A1 (en) 2015-01-28
ES2546287T3 (es) 2015-09-22
IL247351A0 (en) 2016-09-29
HRP20150845T1 (hr) 2015-11-06
PT2288373E (pt) 2015-10-19
IL208992A0 (en) 2011-01-31
CA2724540A1 (en) 2009-11-19
GB2462221A (en) 2010-02-03
EP2288373B1 (en) 2015-06-24
IL228244A (en) 2016-10-31
US9066916B2 (en) 2015-06-30
GB0908432D0 (en) 2009-06-24
GB2462221B (en) 2010-09-01
HK1140693A1 (en) 2010-10-22

Similar Documents

Publication Publication Date Title
AR071810A1 (es) Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
NZ710157A (en) Use of guanethidine for treating hypertension by local vascular delivery
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
AR047779A1 (es) Composiciones y metodos para tratar diabetes
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2016520089A5 (enExample)
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
EA201792030A1 (ru) Лечение пациентов с сахарным диабетом 2 типа
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
CL2021000444A1 (es) Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto.
MX2022003593A (es) Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil.
MX2021011711A (es) Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica.
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
So et al. Effect of compression bandaging on wound healing and psychosocial outcomes in older people with venous ulcers: a randomized controlled trial
AR061635A1 (es) Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos
CL2022000496A1 (es) Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico
RU2006142622A (ru) Способ лечения острого инфаркта миокарда
EA202192612A1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
RU2015134772A (ru) Применение биматопроста для повышения выработки лептина
Lee Phenylephrine/prednisolone acetate
CN109602811A (zh) 一种治疗冠心病的药物
Siddique Is Enhanced External Counterpulsation (EECP) A-Last Resort Treatment of Refractory Angina?

Legal Events

Date Code Title Description
FB Suspension of granting procedure